We are live on ! Find out more
ADCT icon

ADC Therapeutics

58 hedge funds and large institutions have $273M invested in ADC Therapeutics in 2022 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 15 increasing their positions, 9 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

275% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 4

69% more call options, than puts

Call options by funds: $198K | Put options by funds: $117K

67% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 9

18% more funds holding

Funds holding: 4958 (+9)

0.46% more ownership

Funds ownership: 44.43%44.88% (+0.46%)

46% less capital invested

Capital invested by funds: $501M → $273M (-$229M)

67% less funds holding in top 10

Funds holding in top 10: 31 (-2)

Holders
58
Holders Change
+9
Holders Change %
+18.37%
% of All Funds
0.98%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.02%
New
15
Increased
15
Reduced
9
Closed
4
Calls
$198K
Puts
$117K
Net Calls
+$81K
Net Calls Change
-$256K
Name Holding Trade Value Shares
Change
Change in
Stake
Wells Fargo
51
Wells Fargo
California
$2K
MF
52
Magnetar Financial
Illinois
$1.33K
First Manhattan
53
First Manhattan
New York
$1K
VVP
54
Venture Visionary Partners
Ohio
$795 +$946 +100 New
VEA
55
Virtus ETF Advisers
New York
-$282K -19,193 Closed
PFS
56
Prospera Financial Services
Texas
-$87K -5,921 Closed
SOW
57
State of Wyoming
Wyoming
-$42K -2,882 Closed
Carson Wealth (CWM LLC)
58
Carson Wealth (CWM LLC)
Nebraska
-$14K -950 Closed

ADCT Hedge Fund Activity: Q2 2022 in Review

58 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in ADC Therapeutics (ADCT) for Q2 2022, worth a combined $273M — down 46% from $501M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new ADCT positions and 4 closed out — a net gain of 11 holders — while 15 added to existing stakes and 9 trimmed.

The largest buyer was Walleye Capital, adding an estimated $6.06M. The largest seller was T. Rowe Price Associates, cutting an estimated $4.74M.

  • 58 institutional investors held ADC Therapeutics (ADCT) as of Q2 2022, up from 49 in Q1 2022.
  • Funds reported $273M of ADC Therapeutics stock for Q2 2022, down 46% quarter-over-quarter.
  • 15 funds opened new ADC Therapeutics positions in Q2 2022 and 4 closed out, a net change of +11 holders.
  • The largest ADC Therapeutics buyer in Q2 2022 was Walleye Capital, an estimated $6.06M added.
  • The largest ADC Therapeutics seller in Q2 2022 was T. Rowe Price Associates, an estimated $4.74M sold.

Based on aggregated 13F filings for Q2 2022.